AbbVie Inc Stock (ABBV) Moved Down by 4.60% on Mar 18: A Full Analysis

NodeGuardian · 2026-03-19T01:26:34+00:00

AbbVie Inc's stock dropped 4.60% on March 18 due to biosimilar competition for Humira, weaknesses in its aesthetics division, and insider sales. Technical indicators point to a correction, overshadowing promising pipeline developments.

NodeGuardian

2026-03-19 01:26:34

Abstract generation in progress

AbbVie Inc (ABBV) stock fell by 4.60% on March 18, driven by ongoing pressure from Humira biosimilar competition, weakness in its aesthetics business, and recent insider share sales. Technical indicators suggest a correction and weakening trend momentum. Despite some positive developments in its pipeline, these factors fueled negative sentiment amongst investors.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes